Rationale and Design of the Multicentre, Randomized, Double-Blind, Placebo-Controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)

Abstract

Aliskiren is a DRI with a favourable neurohormonal and haemodynamic profile that may benefit patients hospitalized with worsening HF. Given the neurohormonal abnormalities that are present during and after hospitalization for AHFS, it is hypothesized that adding aliskiren to standard therapy will reduce post-discharge mortality and re-hospitalization. NCT00894387.